

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:)
KIROMIC BIOPHARMA, INC.) 25-10552-MFW
Debtor.) Chapter 7

GLOBAL NOTES

KIROMIC BIOPHARMA, INC. (the “Debtor”) is filing its Schedules of Assets and Liabilities (collectively, the “Schedules”) and Statements of Financial Affairs (collectively, the “Statements,” and together with the Schedules, collectively, the “Schedules and Statements”) in the United States Bankruptcy Court for the District of Delaware (the “Court”). The Debtor prepared the Schedules and Statements in accordance with section 521 of title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Bankruptcy Code”), and Rule 1007 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”).

These Global Notes and Statement of Limitations, Methodology and Disclaimer regarding the Schedules and Statements (collectively, the “Global Notes”) pertain to, are incorporated by reference in, and comprise an integral part of, all of the Schedules and Statements. These Global Notes should be referred to as part of, and reviewed in connection with, the Schedules and Statements.

The Schedules and Statements have been prepared based on the Debtor’s knowledge, information and belief, with such information being the best information reasonably available to the Debtor, given that its access to certain systems has been restricted. The Schedules and Statements are unaudited and subject to potential adjustment. In preparing the Schedules and Statements, the Debtor relied on financial data derived from their books and records that was available at the time of preparation.

Subsequent information, data or discovery may result in material changes to the Schedules and Statements, and inadvertent errors, omissions or inaccuracies may exist. The Debtor reserves all rights to amend or supplement the Schedules and Statements as may be necessary and appropriate.

Pietro Bersani has signed each of the Schedules and Statements. Mr. Bersani is an authorized signatory for the Debtor. In reviewing and signing the Schedules and Statements, Mr. Bersani has relied upon the efforts, statements, and representations of various personnel employed by the Debtor and their professional advisors. Mr. Bersani has not (and could not have) personally verified the accuracy of each statement and representation contained in the Schedules and Statements, including statements and representations concerning amounts owed to creditors, classification of such amounts, and creditor addresses.

Reservation of Rights. Reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements; however, inadvertent errors or omissions may exist. The Debtor reserves all rights to (i) amend or supplement the Schedules and Statements from time to time, in all respects, as may be necessary or appropriate, including, without limitation, the right to amend the Schedules and Statements with respect to any description or designation of any claim; (ii) dispute or otherwise assert offsets or defenses to any claim reflected in the Schedules and Statements as to amount, liability, priority, status, classification or otherwise; (iii) subsequently designate any claim as “disputed,” “contingent,” or “unliquidated” or object to the extent, validity, enforceability, priority, avoidability or any other matter in respect of any claim. Listing a claim does not constitute an admission of liability by the Debtor against which the claim is listed. Any specific reservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this paragraph. Notwithstanding the foregoing, the Debtor shall not be required to update the Schedules and Statements except as may be required by applicable law.

No Admission. Nothing contained in the Schedules and Statements is intended as, or should be construed as, an admission or stipulation of the validity of any claim against the Debtor, any assertion made therein or herein, or a waiver of the Debtor's rights to dispute any claim or assert any cause of action or defense against any party.

Description of the Case and "As of" Information Date. On 03/21/2025 (the "Petition Date"), the Debtor filed voluntary petitions for relief with the Court under chapter 7 of the Bankruptcy Code. Unless otherwise indicated herein or in the Schedules and Statements, all financial information for the Debtor in the Schedules and Statements and these Global Notes is provided as of the Petition Date or as close thereto as reasonably practicable under the circumstances.

Fiscal Year. The Debtor's fiscal year ends on December 31st.

Basis of Presentation. The Schedules and Statements do not purport to represent financial statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), nor are they intended to fully reconcile to any financial statements prepared by the Debtor.

Recharacterization. Notwithstanding the Debtor's commercially reasonable efforts to properly characterize, classify, categorize, or designate certain claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and Statements, the Debtor reserves all rights in this regard.

Insiders. For purposes of the Schedules and Statements, the Debtor defines "insiders" pursuant to section 101(31) of the Bankruptcy Code as: (a) current or former directors, officers or persons in control of the Debtor; (b) relatives of current or former directors, officers, or persons in control of the Debtor; (c) a partnership in which one or both of the Debtor is, or are, a general partner; or (d) an affiliate of the Debtor. Except as

otherwise disclosed herein or in the Statements, payments to insiders listed in (a) through (d) above are set forth on Statement 4. Persons listed as “insiders” have been included for informational purposes only, and such listing is not intended to be, nor should it be construed as, a legal characterization of such person as an insider, nor does it serve as an admission of any fact, claim, right or defense, and all such claims, rights, and defenses with respect thereto are hereby expressly reserved. Further, the Debtor does not take any position with respect to: (a) any such person’s influence over the control of the Debtor; (b) the management responsibilities or functions of any such individual; (c) the decision-making or corporate authority of any such individual; or (d) whether any such individual could successfully argue that he or she is not an “insider” under applicable law, including, without limitation, the federal securities laws, or with respect to any theories of liability or for any other purpose.

Credits and Adjustments. Claims of creditors are listed in the amounts entered on the Debtor’s books and records, and may not reflect certain credits, allowances or other adjustments due from such creditors to the Debtor. The Debtor reserves all rights with regard to any such credits, allowances and other adjustments, including, without limitation, the right to assert claims, objections, setoffs and recoupments with respect to the same.

Leases. In the ordinary course of business, the Debtor leases certain real property, fixtures, and equipment from certain third-party lessors for use in the maintenance of their business. Nothing in the Schedules and Statements is, or shall be construed as, an admission as to the determination of the legal status of any lease (including, without limitation, whether any lease is a true lease or a financing arrangement, and whether such lease is unexpired), and the Debtor reserves all rights with respect to such issues.

Estimates. To prepare and file the Schedules and Statements in accordance with the deadline established in the case, the Debtor was required to make certain estimates and assumptions that affected the reported amounts of these assets and liabilities as of

the Petition Date (i.e., April 13, 2023). The Debtor reserves all rights to amend the reported amounts of assets, liabilities, revenue, and expenses to reflect changes in those estimates and assumptions.

Classifications. Listing a claim (a) on Schedule D as “secured,” (b) on Schedule E/F as “unsecured priority,” or “unsecured non-priority,” or (c) listing a contract or lease on Schedule G as “executory” or “unexpired,” does not constitute an admission by the Debtor of the legal rights of any claimant, or a waiver of the rights of the Debtor to recharacterize or reclassify any claim or contract.

Part 10. Schedule A/B, Part 10 identifies the Debtor’s interests in intangibles or intellectual property. Exclusion or inclusion of any intangibles or intellectual property shall not be construed as an admission that such intellectual property rights have or have not been abandoned, terminated, assigned, expired by their terms, or otherwise transferred pursuant to a sale, acquisition, or other transaction.

Schedule D – Creditors Who Have Claims Secured by Property. Amounts listed on Schedule D may not reflect any accrued interest, fees, costs, and other charges that such creditors may be entitled to.

Schedule E/F – Creditors Who Have Unsecured Claims. The Debtor has used commercially reasonable efforts to include all creditors on Part 2 of Schedule E/F. The data used was that available to the declarant as of March 21, 2025.

Schedule G – Executory Contracts and Unexpired Leases. Although commercially reasonable efforts have been made to ensure the accuracy of Schedule G regarding executory contracts and unexpired leases, inadvertent errors, omissions, or over-inclusion may have occurred in preparing Schedule G. Omission of a contract, lease or other agreement from Schedule G does not constitute an admission that such omitted contract, lease or agreement is not an executory contract or unexpired lease.

Statement 3. Statement 3 includes any disbursements or other transfers made by the Debtor within 90 days prior to filing, except for those made to insiders, which are reflected on

Statements 4 and 30. The Debtor did not include payments to non-insider employees in Statements 4 or 30.

Statement 7. The Debtor reserves all rights, claims, and defenses with respect to all listed lawsuits and administrative proceedings (or potential lawsuits and administrative proceedings). The listing of any such lawsuits and proceedings shall not constitute an admission by the Debtor of any liabilities.

Fill in this information to identify the case:

Debtor name KIROMIC BIOPHARMA, INC.
 United States Bankruptcy Court for the: District of Delaware
 Case number (If known): 25-10552-MFW (State)

Check if this is an amended filing

Official Form 206Sum

Summary of Assets and Liabilities for Non-Individuals

12/15

Part 1: Summary of Assets

1. Schedule A/B: Assets-Real and Personal Property (Official Form 206A/B)

1a. Real property:

Copy line 88 from Schedule A/B

\$ 0.00

1b. Total personal property:

Copy line 91A from Schedule A/B.....

\$ 4297952.50

1c. Total of all property:

Copy line 92 from Schedule A/B

\$ 4297952.50

Part 2: Summary of Liabilities

2. Schedule D: Creditors Who Have Claims Secured by Property (Official Form 206D)

Copy the total dollar amount listed in Column A, *Amount of claim*, from line 3 of Schedule D

\$ 14,491,703.00

3. Schedule E/F: Creditors Who Have Unsecured Claims (Official Form 206E/F)

3a. Total claim amounts of priority unsecured claims:

Copy the total claims from Part 1 from line 6a of Schedule E/F.....

\$ 0.00

3b. Total amount of claims of nonpriority amount of unsecured claims:

Copy the total of the amount of claims from Part 2 from line 6b of Schedule E/F.....

+\$ 3,857,043.93

4. Total liabilities

Lines 2 + 3a + 3b

\$ 18,348,746.93

Fill in this information to identify the case:

Debtor name KIROMIC BIOPHARMA, INC.United States Bankruptcy Court for the: District of DelawareCase number (if known): 25-10552-MFW Check if this is an amended filing

Official Form 206A/B

Schedule A/B: Assets — Real and Personal Property

12/15

Disclose all property, real and personal, which the debtor owns or in which the debtor has any other legal, equitable, or future interest. Include all property in which the debtor holds rights and powers exercisable for the debtor's own benefit. Also include assets and properties which have no book value, such as fully depreciated assets or assets that were not capitalized. In Schedule A/B, list any executory contracts or unexpired leases. Also list them on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G).

Be as complete and accurate as possible. If more space is needed, attach a separate sheet to this form. At the top of any pages added, write the debtor's name and case number (if known). Also identify the form and line number to which the additional information applies. If an additional sheet is attached, include the amounts from the attachment in the total for the pertinent part.

For Part 1 through Part 11, list each asset under the appropriate category or attach separate supporting schedules, such as a fixed asset schedule or depreciation schedule, that gives the details for each asset in a particular category. List each asset only once. In valuing the debtor's interest, do not deduct the value of secured claims. See the instructions to understand the terms used in this form.

Part 1: Cash and cash equivalents

1. Does the debtor have any cash or cash equivalents?

No. Go to Part 2.
 Yes. Fill in the information below.

All cash or cash equivalents owned or controlled by the debtor

Current value of debtor's interest

2. Cash on hand

\$ 0.00

3. Checking, savings, money market, or financial brokerage accounts (Identify all)

Name of institution (bank or brokerage firm)	Type of account	Last 4 digits of account number	Current value of debtor's interest
3.1. <u>Bank of America (Payroll)</u>	<u>Checking</u>	<u>6 9 5 4</u>	<u>\$ 75,529.00</u>
3.2. <u>See continuation sheet</u>			<u>\$ 275,070.00</u>

4. Other cash equivalents (Identify all)

4.1. <u>22-6690-JH (Settlement Fund) ~ 70% Contributed by Debtor; balance from Ins. (Other Cash Equivalents)</u>	<u>\$ 2,349,219.38</u>
4.2. _____	<u>\$ _____</u>

5. Total of Part 1

Add lines 2 through 4 (including amounts on any additional sheets). Copy the total to line 80.

\$ 2699818.38

Part 2: Deposits and prepayments

6. Does the debtor have any deposits or prepayments?

No. Go to Part 3.
 Yes. Fill in the information below.

Current value of debtor's interest

7. Deposits, including security deposits and utility deposits

Description, including name of holder of deposit	
7.1. <u>Lease Deposit w. Cambridge International, LLC</u>	<u>\$ 21,353.00</u>
7.2. _____	<u>\$ _____</u>

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

8. Prepayments, including prepayments on executory contracts, leases, insurance, taxes, and rent

Description, including name of holder of prepayment

8.1. Other

\$ 304,010.00

8.2. See continuation sheet

\$ 1,260,896.12

9. Total of Part 2.

Add lines 7 through 8. Copy the total to line 81.

\$ 1,586,259.12

Part 3: Accounts receivable**10. Does the debtor have any accounts receivable?** No. Go to Part 4. Yes. Fill in the information below.

Current value of debtor's interest

11. Accounts receivable11a. 90 days old or less: face amount - doubtful or uncollectible accounts = → \$ _____11b. Over 90 days old: face amount - doubtful or uncollectible accounts = → \$ _____**12. Total of Part 3**

Current value on lines 11a + 11b = line 12. Copy the total to line 82.

\$ _____

Part 4: Investments**13. Does the debtor own any investments?**

No. Go to Part 5.

 Yes. Fill in the information below.

Valuation method used for current value

Current value of debtor's interest

14. Mutual funds or publicly traded stocks not included in Part 1

Name of fund or stock:

14.1. _____ \$ _____

14.2. _____ \$ _____

15. Non-publicly traded stock and interests in incorporated and unincorporated businesses, including any interest in an LLC, partnership, or joint venture

Name of entity:

% of ownership:

15.1. Green Planet Pharma, Inc. 100 % \$ 0
15.2. _____ % \$ _____**16. Government bonds, corporate bonds, and other negotiable and non-negotiable instruments not included in Part 1**

Describe:

16.1. _____ \$ _____

16.2. _____ \$ _____

\$ 0**17. Total of Part 4**

Add lines 14 through 16. Copy the total to line 83.

Debtor

KIROMIC BIOPHARMA, INC.
Name _____

Case number (if known) 25-10552-MFW

Part 5: Inventory, excluding agriculture assets**18. Does the debtor own any inventory (excluding agriculture assets)?**

No. Go to Part 6.
 Yes. Fill in the information below.

General description	Date of the last physical inventory	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
19. Raw materials Vars precursors and reagents	MM / DD / YYYY	0.00 \$ _____	Company Expenses All	Unknown \$ _____
20. Work in progress	MM / DD / YYYY	\$ _____		\$ _____
21. Finished goods, including goods held for resale Packages of Experimental Drug	MM / DD / YYYY	0.00 \$ _____	Not Saleable	Unknown \$ _____
22. Other inventory or supplies	MM / DD / YYYY	\$ _____		\$ _____
23. Total of Part 5				\$ 0.00

Add lines 19 through 22. Copy the total to line 84.

24. Is any of the property listed in Part 5 perishable?

No
 Yes

25. Has any of the property listed in Part 5 been purchased within 20 days before the bankruptcy was filed?

No
 Yes. Book value _____ Valuation method _____ Current value _____

26. Has any of the property listed in Part 5 been appraised by a professional within the last year?

No
 Yes

Part 6: Farming and fishing-related assets (other than titled motor vehicles and land)**27. Does the debtor own or lease any farming and fishing-related assets (other than titled motor vehicles and land)?**

No. Go to Part 7.
 Yes. Fill in the information below.

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
28. Crops—either planted or harvested	\$ _____		\$ _____
29. Farm animals Examples: Livestock, poultry, farm-raised fish	\$ _____		\$ _____
30. Farm machinery and equipment (Other than titled motor vehicles)	\$ _____		\$ _____
31. Farm and fishing supplies, chemicals, and feed	\$ _____		\$ _____
32. Other farming and fishing-related property not already listed in Part 6	\$ _____		\$ _____

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

33. Total of Part 6.

Add lines 28 through 32. Copy the total to line 85.

\$ _____

34. Is the debtor a member of an agricultural cooperative?

No

Yes. Is any of the debtor's property stored at the cooperative?

No

Yes

35. Has any of the property listed in Part 6 been purchased within 20 days before the bankruptcy was filed?

No

Yes. Book value \$ _____ Valuation method _____ Current value \$ _____

36. Is a depreciation schedule available for any of the property listed in Part 6?

No

Yes

37. Has any of the property listed in Part 6 been appraised by a professional within the last year?

No

Yes

Part 7: Office furniture, fixtures, and equipment; and collectibles

38. Does the debtor own or lease any office furniture, fixtures, equipment, or collectibles?

No. Go to Part 8.

Yes. Fill in the information below.

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
39. Office furniture Desk Tables & Chairs (30 desk/chair combos)	\$ _____	Expensed As Purcha: _____	\$ 3,000.00
40. Office fixtures See continuation sheet	\$ 3,666,838.00	_____	\$ Unknown
41. Office equipment, including all computer equipment and communication systems equipment and software See continuation sheet	\$ 0.00	_____	\$ 8,875.00
42. Collectibles Examples: Antiques and figurines; paintings, prints, or other artwork; books, pictures, or other art objects; china and crystal; stamp, coin, or baseball card collections; other collections, memorabilia, or collectibles			
42.1 _____	\$ _____	_____	\$ _____
42.2 _____	\$ _____	_____	\$ _____
42.3 _____	\$ _____	_____	\$ _____
43. Total of Part 7.			\$ 11,875.00

Add lines 39 through 42. Copy the total to line 86.

44. Is a depreciation schedule available for any of the property listed in Part 7?

No

Yes

45. Has any of the property listed in Part 7 been appraised by a professional within the last year?

No

Yes

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

Part 8: Machinery, equipment, and vehicles**46. Does the debtor own or lease any machinery, equipment, or vehicles?**

No. Go to Part 9.
 Yes. Fill in the information below.

General description

Include year, make, model, and identification numbers (i.e., VIN, HIN, or N-number)

Net book value of
debtor's interest
(Where available)Valuation method used
for current valueCurrent value of
debtor's interest**47. Automobiles, vans, trucks, motorcycles, trailers, and titled farm vehicles**

47.1	\$ _____	_____	\$ _____
47.2	\$ _____	_____	\$ _____
47.3	\$ _____	_____	\$ _____
47.4	\$ _____	_____	\$ _____

48. Watercraft, trailers, motors, and related accessories Examples: Boats, trailers, motors, floating homes, personal watercraft, and fishing vessels

48.1	\$ _____	_____	\$ _____
48.2	\$ _____	_____	\$ _____

49. Aircraft and accessories

49.1	\$ _____	_____	\$ _____
49.2	\$ _____	_____	\$ _____

**50. Other machinery, fixtures, and equipment
(excluding farm machinery and equipment)**
Lab Equipment (See Attached List)

\$ 2,045,354.81

\$ Unknown

51. Total of Part 8.

Add lines 47 through 50. Copy the total to line 87.

\$ 0.00

52. Is a depreciation schedule available for any of the property listed in Part 8?

No
 Yes

53. Has any of the property listed in Part 8 been appraised by a professional within the last year?

No
 Yes

Debtor

KIROMIC BIOPHARMA, INC.
Name _____25-10552-MFW
Case number (if known) _____**Part 9: Real property****54. Does the debtor own or lease any real property?**

No. Go to Part 10.
 Yes. Fill in the information below.

55. Any building, other improved real estate, or land which the debtor owns or in which the debtor has an interest

Description and location of property Include street address or other description such as Assessor Parcel Number (APN), and type of property (for example, acreage, factory, warehouse, apartment or office building), if available.	Nature and extent of debtor's interest in property	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
55.1 Corporate office and manufacturing facility - 7707 Fannin Houston	Leashold	\$ 3,666,838.00		\$ Unknown
55.2		\$ _____	_____	\$ _____
55.3		\$ _____	_____	\$ _____
56. Total of Part 9.				\$ 0.00

Add the current value on lines 55.1 through 55.6 and entries from any additional sheets. Copy the total to line 88.

57. Is a depreciation schedule available for any of the property listed in Part 9?

No
 Yes

58. Has any of the property listed in Part 9 been appraised by a professional within the last year?

No
 Yes

Part 10: Intangibles and intellectual property**59. Does the debtor have any interests in intangibles or intellectual property?**

No. Go to Part 11.
 Yes. Fill in the information below.

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60. Patents, copyrights, trademarks, and trade secrets See continuation sheet	\$ 0.00		\$ 0.00
61. Internet domain names and websites Kiromic.com	\$ _____	_____	\$ Unknown
62. Licenses, franchises, and royalties	\$ _____	_____	\$ _____
63. Customer lists, mailing lists, or other compilations Clinical Trial Data	\$ _____	_____	\$ Unknown
64. Other intangibles, or intellectual property	\$ _____	_____	\$ _____
65. Goodwill	\$ _____	_____	\$ _____
66. Total of Part 10.			\$ 0.00

Add lines 60 through 65. Copy the total to line 89.

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

67. Do your lists or records include personally identifiable information of customers (as defined in 11 U.S.C. §§ 101(41A) and 107)?

No
 Yes

68. Is there an amortization or other similar schedule available for any of the property listed in Part 10?

No
 Yes

69. Has any of the property listed in Part 10 been appraised by a professional within the last year?

No
 Yes

Part 11: All other assets

70. Does the debtor own any other assets that have not yet been reported on this form?

Include all interests in executory contracts and unexpired leases not previously reported on this form.

No. Go to Part 12.

X Yes. Fill in the information below.

Current value of
debtor's interest

71. Notes receivable

Description (include name of obligor)

Total face amount — → doubtful or uncollectible amount \$

72. Tax refunds and unused net operating losses (NOLs)

Description (for example, federal, state, local)

Tax year \$
 Tax year \$
 Tax year \$

73. Interests in insurance policies or annuities

\$

74. Causes of action against third parties (whether or not a lawsuit has been filed)

\$ Unknown

The Company believes that there may be claims or causes of action that the Company may be able to assert against S.hield Capital Funding LLC. Due to restriction on access to electronic records and Company personnel, the Debtor has been unable to confirm the potential claims.

75. Other contingent and unliquidated claims or causes of action of every nature, including counterclaims of the debtor and rights to set off claims

\$

Nature of claim

Amount requested \$

76. Trusts, equitable or future interests in property

\$

77. Other property of any kind not already listed Examples: Season tickets, country club membership

\$

\$

78. Total of Part 11.

Add lines 71 through 77. Copy the total to line 90.

\$ Unknown

79. Has any of the property listed in Part 11 been appraised by a professional within the last year?

No
 Yes

Debtor

KIROMIC BIOPHARMA, INC.
Name _____

Case number (if known) 25-10552-MFW

Part 12: Summary

In Part 12 copy all of the totals from the earlier parts of the form.

Type of property	Current value of personal property	Current value of real property
80. Cash, cash equivalents, and financial assets. Copy line 5, Part 1.	\$ 2699818.38	
81. Deposits and prepayments. Copy line 9, Part 2.	\$ 1,586,259.12	
82. Accounts receivable. Copy line 12, Part 3.	\$ 0.00	
83. Investments. Copy line 17, Part 4.	\$ 0.00	
84. Inventory. Copy line 23, Part 5.	\$ 0.00	
85. Farming and fishing-related assets. Copy line 33, Part 6.	\$ 0.00	
86. Office furniture, fixtures, and equipment; and collectibles. Copy line 43, Part 7.	\$ 11,875.00	
87. Machinery, equipment, and vehicles. Copy line 51, Part 8.	\$ 0.00	
88. Real property. Copy line 56, Part 9.	→	\$ 0.00
89. Intangibles and intellectual property. Copy line 66, Part 10.	\$ 0.00	
90. All other assets. Copy line 78, Part 11.	+ \$ 0.00	
91. Total. Add lines 80 through 90 for each column. 91a.	\$ 4297952.50	+ 91b. \$ 0.00
92. Total of all property on Schedule A/B. Lines 91a + 91b = 92.		\$ 4297952.50

Debtor 1

KIROMIC BIOPHARMA, INC.

First Name

Middle Name

Last Name

25-10552-MFW

Case number (if known) _____

Continuation Sheet for Official Form 206 A/B

3) Checking, savings, money market, or financial brokerage accounts

General description	Type of account	Last 4 digits of account number
Bank of America (NIH)	Checking	6967
Balance: 2,000.00		
Bank of America	Checking	8004
Balance: 0.00		
Chase Bank	Savings	9589
Balance: 273,070.00		
Chase Bank	Checking	2057
Balance: 0.00		
Chase Bank	Checking	2115
Balance: 0.00		
Fidelity	Brokerage	2618
Balance: 0.00		

8) Prepayments, including prepayments on executory contracts, leases, insurance, taxes, and rent

General description	Current value
Insurance Prepayments	\$467,471.00
LabCorp Drug Development	\$188,088.00
Stiris Research USA, Inc.	\$605,337.12

40) Office fixtures

General description	Net book value	Valuation method	Current value
Leashold Improvements	3,522,559.00		Unknown
40.2. Leasehold improvements - G&A	144,279.00		Unknown

41) Office equipment, including all computer equipment and communication systems equipment and software

General description	Net book value	Valuation method	Current value
Monitors & TVs (35		Expensed As	1,550.00

Debtor 1 **KIROMIC BIOPHARMA, INC.** Case number (if known) **25-10552-MFW**

First Name	Middle Name	Last Name
------------	-------------	-----------

Continuation Sheet for Official Form 206 A/B

Printers (8)	Expensed As Purchased	575.00
Computers (45 Thinkpads)	Expensed As Purchased	6,750.00

60) Patents, copyrights, trademarks, and trade secrets

General description	Net book value	Valuation method	Current value
Patents (See Owned Patent Report)			Unknown
Assigned Patents (See Assigned / Licensed Patents Report)			Unknown
Trademarks (See Trademark Disclosure Report)			0.00

ASSET DISCLOSURE REPORT

Date Acq	Date Sold	Description	Meth/Life	Cost	Net Book Val
Asset A/C#: 15014 - LHI - R&D					
12/1/2019		Laboratory renovation	SLP / 1.417	19,231.67	0.00
9/1/2020		Vivarium	SLP / 5.667	410,062.05	156,788.44
9/1/2020		GMP	SLP / 5.667	409,435.67	156,548.94
12/1/2020		Stainless Steel Piping	SLP / 5.417	52,501.25	21,000.50
1/1/2021		GMP Improvements	SLP / 5.333	14,610.31	5,935.43
1/1/2021		GMP Improvements	SLP / 5.333	30,326.00	12,319.94
6/1/2021		GMP Improvements	SLP / 5.167	10,000.00	4,677.42
8/1/2021		GMP air exchanges	SLP / 5	56,344.12	27,232.99
9/1/2021		ISO 8 Ante Clean Room for GMP CR	SLP / 5	44,382.50	22,191.25
2/1/2022		GMP Quality Control Lab	SLP / 4.25	452,052.00	230,457.87
3/1/2022		GMP1/Cold/Ware Finish	SLP / 4.167	1,699,830.90	883,912.06
4/1/2022		GMP1	SLP / 4.083	533,154.83	282,898.48
4/1/2022		Laboratory sink at Suite 140	SLP / 4.083	13,256.30	7,033.95
6/1/2022		GMP1.1	SLP / 3.917	1,054,140.25	583,141.41
6/1/2022		Cleanroom	SLP / 3.917	1,896,890.86	1,049,343.88
6/1/2022		Suite 255	SLP / 3.917	72,182.53	39,930.76
9/1/2022		R410A 2-Ton RunTru AC	SLP / 3.667	7,500.00	4,431.83
8/1/2023		Circuit 1 Compressors (2)	SLP / 1.75	38,700.81	25,800.53
8/1/2023		Emon Meter - Suites 144, 290 & 291	SLP / 1.75	8,298.23	5,532.16
8/1/2023		Emon Meter - Suite 200	SLP / 1.75	5,071.30	3,380.87
Asset A/C# totals: 15014 - LHI - R&D (20 assets)				6,827,971.58	3,522,558.71
Asset A/C#: 15016 - LHI - G&A					
3/1/2016		Leasehold improvements	SLP / 7	259,703.97	0.00
3/1/2017		Generator system	SLP / 2.5	22,889.66	0.00
10/1/2019		Electrical upgrade	SLP / 1.583	5,234.98	0.00
12/1/2020		Offices	SLP / 5.417	50,594.57	20,237.82
7/1/2021		Leasehold improvements	SLP / 5	7,536.45	3,517.01
9/1/2021		Camera system	SLP / 5	10,459.12	5,229.56
12/1/2021		Security system 1	SLP / 4.417	22,107.80	10,845.33
12/1/2021		Security system 2	SLP / 4.417	19,988.49	9,805.67
12/1/2021		Various improvements	SLP / 4.417	19,283.66	9,459.92
12/1/2022		Access control system	SLP / 3.417	104,825.31	66,474.58
11/1/2023		Security System	SLP / 2.5	21,587.50	18,709.17
Asset A/C# totals: 15016 - LHI - G&A (11 assets)				544,211.51	144,279.06

Asset AC#: 15024 - Laboratory Equipment - R&D		
10/31/2013	Laboratory Equipment	SLP / 3
12/4/2013	Laboratory Equipment	SLP / 3
12/31/2013	Laboratory Equipment	SLP / 3
4/30/2014	Laboratory Equipment	SLP / 3
6/30/2014	Laboratory Equipment	SLP / 3
12/31/2014	Laboratory Equipment	SLP / 3
3/31/2015	Laboratory Equipment	SLP / 3
9/30/2015	Laboratory Equipment	SLP / 3
12/9/2015	Laboratory Equipment	SLP / 3
4/1/2016	Laboratory Equipment	SLP / 3
4/1/2016	Laboratory Equipment	SLP / 3
7/1/2016	Laboratory Equipment	SLP / 3
8/1/2016	Laboratory Equipment	SLP / 3
11/1/2019	Freezer TSX ULT 600-box A-V & sliding drawer	SLP / 7
11/1/2019	Cellometer K2 SK-150	SLP / 7
11/1/2019	Spectrophotometer; Nonodrop One	SLP / 7
12/1/2019	NovoCyte 3000 and NovoSampler Pro	SLP / 7
12/1/2019	Option Infinite M Plex	SLP / 7
12/1/2019	4D-Nucleofector X Unit FL1	SLP / 7
12/1/2019	4D-Nucleofector Core Unit FL1	SLP / 7
12/1/2019	Gbox Demo XX6 Kit 2	SLP / 7
1/1/2020	Leica DM IL LED Fluo	SLP / 7
2/1/2020	IncuCyte S3 System Package	SLP / 7
2/1/2020	Insert Plate Carrier Smart 2 MBS 96 Spare	SLP / 7
3/1/2020	Heracell Vios 160i CO2 Incubator	SLP / 7
3/1/2020	QPCR Instrument Q 2-Channel F/DNA/RNA	SLP / 7
3/1/2020	Simpliamp Thermal Cycler	SLP / 7
7/1/2020	NC-3000 Fixed Assays Package	SLP / 7
9/1/2020	IVIS Spectrum	SLP / 7
9/1/2020	V3.5 Imorack	SLP / 7
11/1/2020	Sorvall Legent RT Refrigerated Benchtop Centrifuge	SLP / 7
12/1/2020	ULT FZ TSX60086A 115V/60HZ	SLP / 7
12/1/2020	Thermo Scientific ST40 Benchtop Centrifuge w/ TX-750 Rotor	SLP / 7
1/1/2021	AutoMACS Pro Separator	SLP / 7
1/1/2021	CliniMACS Plus Instrument	SLP / 7
1/1/2021	QuickPex SQ 120MM Reader	SLP / 7
3/1/2021	Heracell Vios 160i CO2 Incubator	SLP / 7
3/1/2021	Heracell Vios 160i CO2 Incubator	SLP / 7

3/1/2021	TSX ULT 600-box A-Volt	SLP / 7	12,999.00	7,428.00
3/1/2021	Somnosuite Low Flow Vaporizer	SLP / 7	5,564.20	3,179.54
3/1/2021	Cellometer K2 Image Cytometer	SLP / 7	18,615.00	10,637.13
3/1/2021	Type A2 Bio Safety Cabinet	SLP / 7	9,475.00	5,414.28
3/1/2021	Cell Harvest Pump	SLP / 7	15,126.34	8,643.61
5/1/2021	NovoCyte 3005 Combo	SLP / 7	101,712.40	60,543.10
5/1/2021	IncuCyte S3 System Package	SLP / 7	120,979.35	72,011.52
5/1/2021	GMP Equipment	SLP / 7	147,190.36	87,613.31
6/1/2021	Hettich Rotanta 460R Refrigerated Centrifuge	SLP / 7	5,570.00	3,381.79
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	Laboratory Freezer Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Laboratory Freezer Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Ultra-low Temperature Freezers Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Ultra-low Temperature Freezers Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Ultra-low Temperature Freezers Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Ultra-low Temperature Freezers Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Cabinet Biosafety Stand	SLP / 7	6,144.00	3,876.58
9/1/2021	Cell Dyn Emerald	SLP / 7	10,237.42	6,459.33
12/1/2021	Evos XL Core Mechanical Stage	SLP / 7	11,202.60	7,201.68
1/1/2022	Cabinet Biosafety Stand	SLP / 7	6,691.73	4,540.83
2/1/2022	Cabinet Biosafety Stand	SLP / 7	12,810.00	8,845.00
2/1/2022	Taylor Wharton 10K Liquid Nitrogen Dewar SN562-010-p7	SLP / 7	11,071.30	7,776.28
2/1/2022	Thermo Fisher Scientific UJT21286-10-A44-80 Freezer SN01	SLP / 7	5,600.00	3,933.33
2/1/2022	CO2 Shaking Incubator w/ Flat Mat Platform 120V	SLP / 7	7,100.00	4,986.91
3/1/2022	Mobile Compac5 Multi Patient Anesthesia Center	SLP / 7	8,440.47	5,928.43
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	13,679.22	9,770.87
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	6,640.00	4,821.90
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	6,640.00	4,821.90
5/1/2022	Invitrogen EVOS XL Core Configured Cell Imager with Mecha	SLP / 7	6,640.00	4,821.90
5/1/2022	Invitrogen EVOS XL Core Configured Cell Imager with Mecha	SLP / 7	6,691.73	4,939.14
5/1/2022	Heracell VIOS 160i CO ₂ Incubator Single Chamber	SLP / 7	6,640.00	4,900.95
5/1/2022	Heracell VIOS 160i CO ₂ Incubator Single Chamber	SLP / 7	8,634.00	6,372.70
5/1/2022	Heracell VIOS 160i CO ₂ Incubator Single Chamber	SLP / 7	8,634.00	6,372.70
5/1/2022	Heracell VIOS 160i CO ₂ Incubator Single Chamber	SLP / 7	8,634.00	6,372.70
5/1/2022	Heracell VIOS 160i CO ₂ Incubator Single Chamber	SLP / 7	8,635.77	6,374.02
5/1/2022	Cabinet Biosafety Stand A2 115V 10IN 3FT	SLP / 7	9,237.49	6,818.15
5/1/2022	Cabinet Biosafety Stand A2 115V 10IN 3FT	SLP / 7	9,237.49	6,818.15
5/1/2022	Heracell VIOS 160i CO ₂ Incubator Single Chamber CR SS	SLP / 7	14,296.14	10,551.91
5/1/2022	CelCulture Incubator 170L IR Sensor CO2 Control	SLP / 7	7,328.07	5,408.81

5/1/2022	CelCulture Incubator 170L IR Sensor CO2 Control	SLP / 7	7,328.07	5,408.81
6/1/2022	ThawSTAR Cryo Bags Automated Thawing System	SLP / 7	21,400.95	16,050.72
6/1/2022	PHCbi MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	6,048.78	4,536.59
6/1/2022	T-seal Mobile Hand Unit	SLP / 7	7,553.45	5,665.10
6/1/2022	T-seal Mobile Hand Unit	SLP / 7	7,531.18	5,648.38
6/1/2022	SCDIB Sterile Tube Welder RX	SLP / 7	23,770.50	17,827.88
6/1/2022	SCDIB Sterile Tube Welder RX	SLP / 7	7,776.38	5,082.29
6/1/2022	Flake Ice Maker Modular Scots	SLP / 7	6,250.13	4,687.59
6/1/2022	Fisherbrand Bread Mill 24 Homogenizer	SLP / 7	11,392.50	8,544.37
6/1/2022	Rotanta 460 Benchtop Centrifuge	SLP / 7	3,245.00	2,109.26
6/1/2022	Rotanta 460 Benchtop Centrifuge	SLP / 7	11,392.50	8,544.37
6/1/2022	QStudio Flx96Wfast Inst LPTP 1 System	SLP / 7	32,128.13	24,096.10
6/1/2022	SuperMACS II Separator	SLP / 7	11,828.62	8,871.46
6/1/2022	Cellometer K2 Image Cytometer Laptop	SLP / 5	32,408.33	24,306.26
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	32,408.33	24,306.26
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	32,408.34	24,306.27
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	29,668.00	22,251.00
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	29,668.00	22,251.00
6/1/2022	Welder PVC TSCD ii F/Sterile Tubing	SLP / 7	20,906.44	15,679.83
6/1/2022	Measuring Equipment	SLP / 7	147,924.75	110,943.56
6/1/2022	GeJacket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GeJacket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GeJacket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GeJacket Stackable CO2 Incubators	SLP / 7	36,355.11	27,266.33
6/1/2022	GeJacket Stackable CO2 Incubators	SLP / 7	17,833.79	13,375.34
6/1/2022	GeJacket Stackable CO2 Incubators	SLP / 7	17,833.79	13,375.34
6/1/2022	Incubator Ref Touchscreen 33CF 115/60	SLP / 7	21,716.37	16,287.27
7/1/2022	PHCbi Laboratory Refrigerator 48.2 cu ft.	SLP / 7	8,363.42	6,372.14
7/1/2022	PHCbi MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,998.78	4,570.51
7/1/2022	Panasonic 24.4 C Ft. Manual Defrost -30C Upright Freezer	SLP / 7	6,892.88	5,251.71
8/1/2022	Eppendorf™ Model 5430R Microcentrifuges	SLP / 7	7,926.40	6,133.53
8/1/2022	1300 Series Class II Type A2 Biological Safety Cabinet	SLP / 7	9,271.00	7,173.98
8/1/2022	Toshiba E3015AC Color MFP Printer	SLP / 5	6,702.03	4,579.72
9/1/2022	IRTD 400 Standard (M2801) System	SLP / 7	5,554.50	4,364.24
9/1/2022	Chart MVE 819P-190F-GB	SLP / 7	19,731.56	15,503.37
9/1/2022	Chart MVE 1536P-190AF-GB High Efficiency/Mapor Series	SLP / 7	25,925.75	20,370.23
9/1/2022	PHCbi MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90
9/1/2022	PHCbi MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90
9/1/2022	PHCbi MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90

9/1/2022	PHCbi MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90
9/1/2022	VIP Eco Upright Ultra Low Temperature Freezer w Natural Re	SLP / 7	17,158.83	13,481.94
9/1/2022	Panasonic MCO-801CL-PA CytoGrow	SLP / 7	16,398.64	12,884.65
9/1/2022	Panasonic MCO-801CL-PA CytoGrow	SLP / 7	16,398.63	12,884.64
9/1/2022	6 Fix96wfast Instlptp 1 System	SLP / 7	36,067.01	28,338.36
9/1/2022	TSCD II Sterile Tube Welder	SLP / 7	23,304.58	18,310.73
9/1/2022	Instrument Infinite 200 Pro Option M Plex	SLP / 7	25,139.52	19,752.48
10/1/2022	Kaye Temperature Sensor	SLP / 7	83,803.00	66,842.86
10/1/2022	Geldoc Go Imaging System	SLP / 7	12,024.34	9,590.84
10/1/2022	Type A2 Biological Safety Cabinet	1300 Series Class II	SLP / 7	9,271.00
10/1/2022	Type A2 Biological Safety Cabinet	1300 Series Class II	SLP / 7	9,271.00
10/1/2022	Type A2 Biological Safety Cabinet	1300 Series Class II	SLP / 7	9,271.00
10/1/2022	Type A2 Biological Safety Cabinet	1300 Series Class II	SLP / 7	9,271.00
10/1/2022	Type A2 Biological Safety Cabinet	1300 Series Class II	SLP / 7	9,271.00
10/1/2022	Type A2 Biological Safety Cabinet	1300 Series Class II	SLP / 7	9,271.00
10/1/2022	CliniMACS Plus Instrument	SLP / 7	104,890.00	83,662.26
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
12/1/2022	Freezer - Panasonic 24.4 CF Manual Defrost -30C Upright 11	SLP / 7	6,992.68	5,743.98
12/1/2022	Freezer - CryoMed w OPC UA General Purpose w Printer 1.7	SLP / 7	24,745.32	20,326.50
9/1/2023	LN2 Freezer - S-1500AB LN2 Storage System	SLP / 7	15,101.07	14,022.41
11/1/2023	PTS Nexgen Instrument Kit	SLP / 7	69,265.10	65,966.77
1/1/2024	PTS Nexgen Instrument Kit	SLP / 7	9,760.00	9,527.62
			3,135,990.08	1,948,786.48
Asset A/C# totals: 15024 - Laboratory Equipment - R&D (142 assets)				
Asset A/C#: 15036 - Office Fur, Fix & Equipment - G&A				
1/1/2018	Website upgrade	SLP / 5	10,110.00	0.00
7/1/2019	Dell Precision 7920 Tower	SLP / 5	6,492.45	432.83
2/1/2022	Fire Alarm System	SLP / 5	8,114.04	4,733.20
2/1/2022	Offsite Network System	SLP / 5	64,575.90	37,669.27
2/1/2022	Onsite Network System	SLP / 5	20,225.87	11,798.42
5/1/2022	1U Supermicro SuperServer	SLP / 5	13,880.00	8,790.67
5/1/2022	1U Supermicro SuperServer	SLP / 5	13,880.00	8,790.67
			137,278.26	72,215.06
Asset A/C# totals: 15036 - Office Fur, Fix & Equipment - G&A (7 assets)				
Asset A/C#: 15044 - Software - R&D				
10/1/2018	KAI Software	SLP / 5	121,505.45	0.00
2/1/2019	Cancer Specific Alt Splicing Software	SLP / 5	20,000.00	0.00

8/1/2020	Cancer Specific Alt Splicing Software	10,250.00	0.00
8/1/2021	Incucyte Cell-by-Cell Software	20,423.53	2,836.61
8/1/2021	Bioinformatics Protein Research Software	39,335.00	5,463.19
Asset A/C# totals: 15044 - Software - R&D (5 assets)			<u>211,513.98</u>
Asset A/C# 15046 - Software - G&A			<u>8,299.80</u>
7/1/2021	P2P software	SLP / 3	
9/1/2021	P2P software enhancement	SLP / 2,833	
10/1/2021	P2P software enhancement	SLP / 2,583	
11/1/2021	P2P software enhancement	SLP / 2,667	
Asset A/C# totals: 15046 - Software - G&A (4 assets)			<u>148,000.00</u>
Grand Totals: (189 assets)			<u>11,004,965.41</u>
			<u>5,712,192.81</u>

TRADEMARK DISCLOSURE REPORT

MARK / TITLE	COUNTRY	STATUS	APPLICATION NUMBER	DATE FILED	REGISTRATION NUMBER	REGISTRATION DATE
ALEXIS-ISO-1	United States of America	Abandoned	97/126,855	Nov 16, 2021		
ALEXIS-PRO-1	United States of America	Abandoned	97/120,489	Nov 11, 2021		
BLADE-SMART	United States of America	Abandoned	87191715	Oct 3, 2016		
BRIGHTSPRING	United States of America	Abandoned	88727418	Dec 14, 2019		
CHPD1-GDT	United States of America	Abandoned	97/127,015	Nov 16, 2021		
DELTACEL	United States of America	Allowed	97/444,141	Jun 6, 2022		
DIAMOND AI	United States of America	Registered	90265700	Oct 20, 2020	6410921	Jul 6, 2021
DIAMOND AI ARTIFICIAL INTELLIGENCE NEURAL NETWORK & DESIGN	United States of America	Abandoned	97/145,994	Nov 29, 2021		
DIAMOND ARTIFICIAL INTELLIGENCE (DAI)	United States of America	Abandoned	88336671	Mar 12, 2019		
EPITCR	United States of America	Abandoned	87770341	Jan 25, 2018		
EPITOPTCR	United States of America	Abandoned	87770254	Jan 25, 2018		
GAMMACEL	United States of America	Abandoned	97/194,538	Dec 29, 2021		

GREENPLANET PHARMA.	United States of America	Abandoned	88156752	Oct 16, 2018	
ICAR-ISO-GDT	United States of America	Abandoned	97/129,232	Nov 17, 2021	
ISOCEL	United States of America	Abandoned	97/145,914	Nov 29, 2021	
ISOCEL	United States of America	Abandoned	97/484,087	Jun 30, 2022	
KEY TO CANCER'S CURE	United States of America	Lapsed	860333393	Aug 9, 2013	5073577
KIROMIC	United States of America	Abandoned	97/484,071	Jun 30, 2022	Nov 1, 2016
KIROMIC	United States of America	Lapsed	860333737	Aug 9, 2013	5073579
KIROMIC	United States of America	Registered	90264426	Oct 19, 2020	6410841
KIROMIC & Sun Design	United States of America	Allowed	97/484,081	Jun 30, 2022	Jul 6, 2021
KIROTOPES	United States of America	Registered	90264447	Oct 19, 2020	6410847
KIROTOPES	United States of America	Abandoned	87769734	Jan 25, 2018	
MAKING CANCER EXIT	United States of America	Abandoned	98/325,991	Dec 21, 2023	
MISCELLANEOUS DESIGN	United States of America	Abandoned	97/110,809	Nov 5, 2021	
NEOMUTAEPITOPES	United States of America	Abandoned	87769923	Jan 25, 2018	
PROCEL	United States of America	Abandoned	97/141,500	Nov 24, 2021	
PROCEL	United States of America	Abandoned	97/484,095	Jun 30, 2022	

SOOTHING SPRING	United States of America	Abandoned	88727158	Dec 13, 2019		
TESLA CAR-T	United States of America	Abandoned	97/110,989	Nov 5, 2021		
THE TESLA OF CAR-T	United States of America	Abandoned	97/110,937	Nov 5, 2021		
THE TESLA OF IMMUNOTHERAPY	United States of America	Abandoned	97/106,801	Nov 3, 2021		
WHERE AI & DATA MINING MEETS CANCER IMMUNOTHERAPY	United States of America	Abandoned	97/106,294	Nov 3, 2021		

OWNED PATENT DISCLOSURE REPORT

APPLICATION NUMBER	DATE FILED	COUNTRY	STATUS	PUBLICATION NUMBER	PUBLICATION DATE	PATENT NUMBER	GRANT DATE	
PCT/US2020/035183	May 29, 2020	PCT	Expired	WO/2020/243469	Dec 3, 2020			Methods for identifying and using disease-associate
20760613.8	May 29, 2020	European Patent Office	Published	3977460	Apr 6, 2022			Methods for identifying and using disease-associate
17/613,191	May 29, 2020	United States of America	Published	2022-0310200	Sep 29, 2022			Methods for identifying and using disease-associate
62/921,127	May 31, 2019	United States of America	Expired					Methods for identifying and using disease-associate
PCT/US2021/040348	Jul 2, 2021	PCT	Expired	WO 2022/010798	Jan 13, 2022			Methods for identifying and using disease-associate
21755850.1	Jul 2, 2021	European Patent Office	Published	4175650	May 10, 2023			Methods for identifying and using disease-associate
18/004,158	Jul 2, 2021	United States of America	Published	2024-0279353	Aug 22, 2024			Methods for identifying and using disease-associate

63/048,488	Jul 6, 2020	United States of America	Expired	MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE GAMMA-DELTA CELL MANUFACTURIN G PROCESSES AND CHIMERIC PD1 RECEPTOR MOLECULES, Gamma-delta t cell manufacturing processes and chimeric pd1	https://pubs.uspto.gov/directsearch/public/print/dowmloadBasicPdf/20240279353?requestToken=eyJrIjwQ1MjcxOS0MDAxLQ2YzEYmU5MjV1MzMyZTyzYzg0ZlCjZXj0i4Zlk2YmFxZC1kNjM0LjQ1MmFyMjM3MmE5u20ZmM3MzEiLjleH4Qb9
63/115,465	Nov 18, 2020	United States of America	Expired	MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE GAMMA-DELTA CELL MANUFACTURIN G PROCESSES AND CHIMERIC PD1 RECEPTOR MOLECULES, Gamma-delta t cell manufacturing processes and chimeric pd1	https://pubs.uspto.gov/directsearch/public/print/dowmloadBasicPdf/20240279353?requestToken=eyJrIjwQ1MjcxOS0MDAxLQ2YzEYmU5MjV1MzMyZTyzYzg0ZlCjZXj0i4Zlk2YmFxZC1kNjM0LjQ1MmFyMjM3MmE5u20ZmM3MzEiLjleH4Qb9
63/185,790	May 7, 2021	United States of America	Expired	MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE GAMMA-DELTA CELL MANUFACTURIN G PROCESSES AND CHIMERIC PD1 RECEPTOR MOLECULES, Gamma-delta t cell manufacturing processes and chimeric pd1	https://pubs.uspto.gov/directsearch/public/print/dowmloadBasicPdf/20240279353?requestToken=eyJrIjwQ1MjcxOS0MDAxLQ2YzEYmU5MjV1MzMyZTyzYzg0ZlCjZXj0i4Zlk2YmFxZC1kNjM0LjQ1MmFyMjM3MmE5u20ZmM3MzEiLjleH4Qb9
63/243,524	Sep 13, 2021	United States of America	Expired	MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE GAMMA-DELTA CELL MANUFACTURIN G PROCESSES AND CHIMERIC PD1 RECEPTOR MOLECULES, Gamma-delta t cell manufacturing processes and chimeric pd1	https://pubs.uspto.gov/directsearch/public/print/dowmloadBasicPdf/20240279353?requestToken=eyJrIjwQ1MjcxOS0MDAxLQ2YzEYmU5MjV1MzMyZTyzYzg0ZlCjZXj0i4Zlk2YmFxZC1kNjM0LjQ1MmFyMjM3MmE5u20ZmM3MzEiLjleH4Qb9
PCT/US2021/040365	Jul 2, 2021	PCT	Expired	WO 2022/108627	May 27, 2022
3,202,233	Jul 2, 2021	Canada	Pending		

PCT/US2021/059652	Nov 17, 2021	PCT	Expired	MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PDI RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/disearch-public/print/dowloadBasicRdf/20240293544?requestToken=evjzdwIiOihYwQMTcx0S0-MDQ0L1Q2YzEYmU5Mw1IM2M4ZTY2zg0ZjelC122XiiO14Z1k2YmExZC1knjM0L1Q1mEtYmE0M3MmE5N210ZmM3MzElC1leHai0JB9
21939966.4	Nov 17, 2021	European Patent Office	Published	4333983	Mar 13, 2024
62024096321.0	Nov 17, 2021	Hong Kong	Published	40107531	Oct 18, 2024
18/558,701	Nov 17, 2021	United States of America	Published	2024-0293544	Sep 5, 2024
PCT/US2021/058436	Nov 8, 2021	PCT	Expired	MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PDI RECEPTOR MOLECULES, CELLS	https://www.worldwide.espacenet.com/patent/search?p=3D4333983A1
218953594	Nov 8, 2021	European Patent Office	Published	4248368	Sep 27, 2023
18/037,756	Nov 8, 2021	United States of America	Published	2023-0420077	Dec 28, 2023
63/115,356	Nov 18, 2020	United States of America	Expired	DISEASE-ASSOCIA TED ISOFORM IDENTIFIER	https://www.worldwide.espacenet.com/patent/search?q=pn%3D4248368A1
PCT/US2021/031387	May 7, 2021	PCT	Expired	PEPTIDE COMPOSITIONS FOR THE TREATMENT OF PATHOGENIC	https://www.worldwide.espacenet.com/patent/search?fa=mly/076250433/publication/WO2021126520A1?&WO_2021/226520

63/101,640	May 8, 2020	United States of America	Expired	Could not verify not in public database
63/094,528	Oct 21, 2020	United States of America	Expired	Could not verify not in public database
21180389.5	Nov 19, 2015	European Patent Office	Abandoned	3903787 Nov 3, 2021
				NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGENANCIES NOVEL
15861304.2	Nov 19, 2015	Belgium	Issued	3220913 Sep 8, 2021
				NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGENANCIES NOVEL
				https://worldwide.espacenet.com/patent/search?q=%23DEP3903787A1
15861304.2	Nov 19, 2015	Switzerland	Issued	3220913 Sep 8, 2021
				NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGENANCIES NOVEL
				https://worldwide.espacenet.com/patent/search?q=%23DEP3220913A1
15861304.2	Nov 19, 2015	Germany	Issued	3220913 Sep 8, 2021
				NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGENANCIES NOVEL
				https://worldwide.espacenet.com/patent/search?q=%23DEP3220913A1

15861304.2	Nov 19, 2015	Denmark	Abandoned	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGNANCIES	https://worldwide.espacenet.com/patent/search?q=epn%3DDE3220913A1		
15861304.2	Nov 19, 2015	European Patent Office	Issued	3220913	Sep 27, 2017	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGNANCIES	https://worldwide.espacenet.com/patent/search?q=epn%3DDE3220913A1
15861304.2	Nov 19, 2015	France	Abandoned	3220913	Sep 8, 2021	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGNANCIES	https://worldwide.espacenet.com/patent/search?q=epn%3DDE3220913A1
15861304.2	Nov 19, 2015	United Kingdom	Issued	3220913	Sep 8, 2021	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGNANCIES	https://worldwide.espacenet.com/patent/search?q=epn%3DDE3220913A1
15861304.2	Nov 19, 2015	United Kingdom	Issued	3220913	Sep 8, 2021	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGNANCIES	https://worldwide.espacenet.com/patent/search?q=epn%3DDE3220913A1
15861304.2	Nov 19, 2015	Ireland	Issued	3220913	Sep 8, 2021	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MAIGNANCIES	https://worldwide.espacenet.com/patent/search?q=epn%3DDE3220913A1

15861304.2	Nov 19, 2015	Italy	Issued	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?p1=%3D&p2=20913A1	
15861304.2	Nov 19, 2015	Monaco	Issued	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?p1=%3D&p2=20913A1	
PCT/US2017/022168	Mar 13, 2017	PCT	Expired	WO/2017/160761	Sep 21, 2017	Compositions and methods for treating cancers	https://pubs.uspto.gov/dssearch-public/print/downloadBasicPdf/10/17774?requestToken=eyJjdWIiOiIhyWQ1MtcKoSzMDQkLTQ2YEtvnU5Mv1MzWmZT%Y2%z0ZicUJ22Xli0i4ZLk2Ymf%ZC1knJN%0L%Q1N%EtYnE0M503MvnE5N210ZrnM3M2eIcLcHai0B9	
201780017624.6	Mar 13, 2017	China	Abandoned	109310738	Feb 5, 2019	Compositions and methods for treating cancers	https://worldwide.espacenet.com/patent/search?p1=%3DCN109310738A	
17767289.6	Mar 13, 2017	European Patent Office	Abandoned	3429613	Jan 23, 2019	Compositions and methods for treating cancers	https://worldwide.espacenet.com/patent/search?p1=%3D&p2=29613A2	
MX/a/2018/011046	Mar 13, 2017	Mexico	Abandoned			Could not verify-not in public database	Likely same as above	
16/082,363	Mar 13, 2017	United States of America	Expired	2019-0031732	Jan 31, 2019	10,717,774	Jul 21, 2020	Compositions and methods for treating cancers
PCT/US2023/068753	Jun 20, 2023	PCT	Expired	WO 2023/250336	Dec 28, 2023			https://worldwide.espacenet.com/patent/search?p1=%3D&p2=2019031732A1
23827993.9	Jun 20, 2023	European Patent Office	Pending			Could not verify-not in public database		
18/876,630	Jun 20, 2023	United States of America	Pending			Could not verify-not in public database		

63/354,027	Jun 21, 2022	United States of America	Expired	Could not verify - not in public database
63/354,045	Jun 21, 2022	United States of America	Expired	Could not verify - not in public database
63/389,308	Jul 14, 2022	United States of America	Abandoned	Could not verify - not in public database

APPLICATION NUMBER	NUMBER OF RECORDED DOCUMENTS	REEL/FRAME NUMBER	CONVEYANCE	ASSIGNOR(S)	ASSESSMENT	EXECUTION DATE	DATE RECORDED
		059053/0199	Assignment of Assignors Interest	Leonardo MIRANDOLA; Maurizio CHIRIVA-INTERNATI	KIROMIC BIOPHARMA, INC.	Jun 18, 2020	Feb 18, 2022
		064841/0397	Change of Name	KIROMIC, INC.	KIROMIC BIOPHARMA, INC.	Dec 16, 2019	Sep 8, 2023
		059191/0275	Assignment of Assignors Interest	KIROMIC, INC.	KIROMIC BIOPHARMA, INC.	Dec 16, 2019	Feb 18, 2022
18/037,756	1	067410/0603	Assignment of Assignors Interest	Zahra TIMSAH; David SPENCER	KIROMIC, INC.	Mar 24, 2017	Feb 18, 2022
		064841/0397	Change of Name	Leonardo MIRANDOLA; Maurizio CHIRIVA-INTERNATI; Lucia PICCOTTI; Michael RYAN	KIROMIC BIOPHARMA, INC.	Nov 9, 2021	May 14, 2024
		052143/0019	Assignment of Assignors Interest	Maurizio CHIRIVA-INTERNATI; Leonardo MIRANDOLA	KIROMIC BIOPHARMA, INC.	Dec 16, 2019	Sep 8, 2023
				KIROMIC, INC.	May 26, 2017	Mar 17, 2020	

Fill in this information to identify the case:

Debtor name KIROMIC BIOPHARMA, INC.

United States Bankruptcy Court for the: District of Delaware

Case number (If known): 25-10552-MFW

 Check if this is an amended filing

Official Form 206D

Schedule D: Creditors Who Have Claims Secured by Property

12/15

Be as complete and accurate as possible.

1. Do any creditors have claims secured by debtor's property?

No. Check this box and submit page 1 of this form to the court with debtor's other schedules. Debtor has nothing else to report on this form.

Yes. Fill in all of the information below.

Part 1: List Creditors Who Have Secured Claims

2. List in alphabetical order all creditors who have secured claims. If a creditor has more than one secured claim, list the creditor separately for each claim.

2.1 Creditor's name

JPMorgan Chase Bank, N.A.,

Describe debtor's property that is subject to a lien

JPM Bank Account

Column A
Amount of claim
Do not deduct the value
of collateral.

Column B
Value of collateral
that supports this
claim

\$ 252,000.00 \$ 273,070.00

Creditor's mailing address

P.O. Box 182108

Internal Mail OHW-1000, Columbus, OH 43

Describe the lien

Agreement you made, Chase supplied a \$12

Is the creditor an insider or related party?

No

Yes

Is anyone else liable on this claim?

No

Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

Contingent

Unliquidated

Disputed

2.2 Creditor's name

S.hield Capital Funding LLC

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$ 2,000,000.00 \$ 0.00

Creditor's mailing address

6238 Los Altos

El Paso, TX 79912

Describe the lien

Is the creditor an insider or related party?

No

Yes

Is anyone else liable on this claim?

No

Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

Contingent

Unliquidated

Disputed

3. Total of the dollar amounts from Part 1, Column A, including the amounts from the Additional Page, if any.

\$ 14,491,703.00

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

Part 1: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page.

2.3 Creditor's name
S.hield Cap1tal Funding LLC

Creditor's mailing address
6233 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 5/1/24

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

No
 Yes. Have you already specified the relative priority?
 No. Specify each creditor, including this creditor, and its relative priority.

Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$2,000,000.00 \$0.00

2.4 Creditor's name
S.hield Cap1tal Funding LLC

Creditor's mailing address

6234 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 7/3/24

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

No
 Yes. Have you already specified the relative priority?
 No. Specify each creditor, including this creditor, and its relative priority.

Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$2,000,000.00 \$0.00

Describe the lien

Is the creditor an insider or related party?

No
 Yes

Is anyone else liable on this claim?

No
 Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

Contingent
 Unliquidated
 Disputed

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

Part 1: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page.

2.5 Creditor's name
S.hield Cap1tal Funding LLC

Creditor's mailing address
6235 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 6/21/24

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

No

Yes. Have you already specified the relative priority?

No. Specify each creditor, including this creditor, and its relative priority.

Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$1,239,703.00

\$0.00

Describe the lien

Is the creditor an insider or related party?

No
 Yes

Is anyone else liable on this claim?

No
 Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

Contingent
 Unliquidated
 Disputed

2.6 Creditor's name
S.hield Cap1tal Funding LLC

Creditor's mailing address

6232 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 4/2/24

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

No

Yes. Have you already specified the relative priority?

No. Specify each creditor, including this creditor, and its relative priority.

Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$2,000,000.00

\$0.00

Describe the lien

Is the creditor an insider or related party?

No
 Yes

Is anyone else liable on this claim?

No
 Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

Contingent
 Unliquidated
 Disputed

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

Part 1: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page.

2.7 Creditor's name
S.hield Capital Funding LLCCreditor's mailing address
6237 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 8/1/2024

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

No

Yes. Have you already specified the relative priority?

No. Specify each creditor, including this creditor, and its relative priority.

 Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$2,000,000.00 \$ 0.00

2.8 Creditor's name
S.hield Capital Funding LLCCreditor's mailing address
6236 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 7/3/24

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

No

Yes. Have you already specified the relative priority?

No. Specify each creditor, including this creditor, and its relative priority.

 Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$2,000,000.00 \$ 0.00

Describe the lien

Is the creditor an insider or related party?

No

Yes

Is anyone else liable on this claim?

No

Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

Contingent

Unliquidated

Disputed

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

Part 1: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page.

2.9 Creditor's name
S.hield Capital Funding LLC

Creditor's mailing address

6239 Los Altos
El Paso, TX 79912

Creditor's email address, if known

Date debt was incurred 1/28/25

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

 No Yes. Have you already specified the relative priority? No. Specify each creditor, including this creditor, and its relative priority. Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

(i) all fixtures (as defined in the UCC) and equipment (as defined in the UCC), (ii) all Intellectual Property, and (iii) all proceeds of the foregoing.

\$1,000,000.00 \$0.00

Describe the lien

Is the creditor an insider or related party?

 No
 Yes

Is anyone else liable on this claim?

 No
 Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

 Contingent
 Unliquidated
 Disputed

2. Creditor's name

Creditor's mailing address

Creditor's email address, if known

Date debt was incurred

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

 No Yes. Have you already specified the relative priority? No. Specify each creditor, including this creditor, and its relative priority. Yes. The relative priority of creditors is specified on lines _____

Describe debtor's property that is subject to a lien

\$ _____ \$ _____

Describe the lien

Is the creditor an insider or related party?

 No
 Yes

Is anyone else liable on this claim?

 No
 Yes. Fill out Schedule H: Codebtors (Official Form 206H).

As of the petition filing date, the claim is:

Check all that apply.

 Contingent
 Unliquidated
 Disputed

Debtor

KIROMIC BIOPHARMA, INC.
Name

Case number (if known) 25-10552-MFW

Part 2: List Others to Be Notified for a Debt Already Listed in Part 1

List in alphabetical order any others who must be notified for a debt already listed in Part 1. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for secured creditors.

If no others need to be notified for the debts listed in Part 1, do not fill out or submit this page. If additional pages are needed, copy this page.

Name and address

On which line in Part 1
did you enter the
related creditor?Last 4 digits of
account number
for this entity

Line 2. _____

Line 2. _____